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for non-signal knee with OV as predictors (R2 > 0.09). Over 80% of the
correlations between DThCtAB and DOutcome examined had p-values
<0.05 at 1 and 3 Years, with most (13 of 22 at 1 Year and 12 of 20
at 3 Years) non-signiﬁcant correlations observed with Incidence cohort.
Correlation between DThCtAB at 1 Year and DOutcome at 3 Years was
signiﬁcant (p < 0.05) after adjusting for DOutcome at 1 Year for nearly all
outcomes.
Conclusions: DThCtAB at 1 year helps predict DOutcome at 3 Years even
after adjusting for DOutcome at 1 Year. The use of ordered values (OV)
as predictors produced larger R2 than use of subregion DThCtAB Results.
Non-signal knees of Progression cohort had larger R2 than signal knees.
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ENHANCED COMP CATABOLISM DETECTED IN SERUM OF PATIENTS
WITH ARTHRITIS AND ANIMAL MODELS THROUGH A NOVEL
CAPTURE ELISA
Y. Lai1, Y. Zhang1, Q. Tian1, H. Song1, M.T. Mucignat2, R. Perris2,
M. Attur1, J.D. Greenberg1, S.B. Abramson1, P.E. Di Cesare3, C-J. Liu1.
1New York Univ., New York, NY, USA; 2Univ. of Parma, Parma, Italy; 3UC
Davis Med. Ctr., Sacramento, CA, USA
Purpose: There are several commercial enzyme-linked immunosorbent
assay (ELISA) kits available for measuring COMP levels in human serum;
however, these reagents lack speciﬁcity for degraded COMP fragments,
which may hinder the usefulness of the test for the clinical monitoring
of arthritis. The goal of this study is to develop a COMP fragment ELISA
to measure levels of proteolytic COMP fragments in serum, and to
determine whether detection of COMP degradative fragments will be
a more sensitive biomarker of arthritis.
Methods:We generated a panel of monoclonal antibodies (mAbs) against
COMP fragments and then characterized the mAbs domain speciﬁcity.
We developed a novel capture ELISA for detecting COMP fragments and
utilized this new test to measure the amount of degradative COMP
fragments in patients with osteoarthritis (OA) and rheumatoid arthritis
(RA). This test was also developed as an assay for the possible monitoring
of the effects of interventions. This new test was then used to monitor
OA progression in surgically induced OA animal models as well as the
alteration in COMP fragment levels in response to biological treatments
in collagen-induced arthritis (CIA) and TNF transgenic animal models.
Results: A panel of murine mAbs against recombinant COMP fragments
was generated and one of these clones, 2127F 5B6, was identiﬁed
as a mAb preferentially recognizing the COMP C-terminal degradative
fragments. A novel COMP fragment ELISA was then developed using
mAb 2127F 5 as a detection antibody. Compared with a commercial
COMP ELISA kit that detected no signiﬁcant difference in total COMP
levels between symptomatic knee OA (SKOA) and non-OA control groups,
a signiﬁcant increase of the COMP fragments was noted in the serum
of SKOA patients assayed by this newly established COMP ELISA. In
addition, serum COMP fragment levels were well correlated with the
Kellgren-Lawrence grade score in OA patients and the progression of
surgically induced OA in murine models. Furthermore, the levels of COMP
fragments in the serum of RA patients, mice with CIA, and TNF transgenic
mice were signiﬁcantly higher when compared with their corresponding
controls. Interestingly, treatments with TNFa inhibitors and methotrexate
led to a signiﬁcant decrease of serum COMP fragments in RA patients.
Additionally, administration of Atsttrin, a progranulin-derived engineered
protein that binds to TNFR and has potent anti-inﬂammatory activity
(Tang, et al, Science, 2011 Apr 22; 332(6028):478–484), also resulted in a
signiﬁcant reduction in serum COMP fragments in several inﬂammatory
arthritis mice models.
Conclusions: Using recombinant COMP fragments we have generated a
series of mAbs that recognize different domains on the COMP protein.
One of these antibodies that bind to the C-terminal portion of the
molecule was then used to develop a novel sandwich ELISA capable of
reproducibly measuring the levels of COMP fragments (COMP catabolism)
in the body ﬂuids of both arthritic patients and murine arthritis models.
In addition, this new test provides a valuable means to utilize serum
COMP fragments as a biomarker for monitoring the effects of therapeutic
interventions on arthritis.
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FEASIBILITY OF LARGE-SCALE ASSESSMENT OF BIOCHEMICAL
MARKERS FOR OSTEOARTHRITIS: AN ANALYSIS IN CHECK
W.E. van Spil1, N.W. Jansen1, J.W. Bijlsma1, M. Reijman2, J. DeGroot3,
P.M. Welsing1, F.P. Lafeber1. 1Univ. Med. Ctr. Utrecht, Utrecht, Netherlands;
2Erasmus Med. Ctr., Rotterdam, Netherlands; 3TNO Quality of Life, Zeist,
Netherlands
Purpose: Osteoarthritis (OA) is currently regarded as a complex joint
disease; multiple articular and peri-articular structures being involved,
probably in a variable sequence and dominance between individuals.
However, current literature on biochemical OA markers mainly concerns
small-scale assessments of limited numbers of biochemical markers and
is thereby discordant with this view. Instead, large-scale assessment
of multiple biochemical markers is preferable. Large-scale assessment
might be regarded unfeasible because of complex logistics, high ﬁnancial
burden, and the increased risk of inducing technical variability. This
publication analyzes the feasibility of such a large-scale assessment of a
wide spectrum of biochemical markers.
Methods: Eleven biochemical markers (CTX-II, COMP, CS846, PIIANP, C1,2C,
CTX-I, NTX-I, OC, PINP, PIIINP, HA) were assessed in urine or serum
samples of 1002 participants (Cohort Hip & Cohort Knee; CHECK) by
means of ELISA and RIA in an academic laboratory and commercially-
independent setting. The assessment was necessarily performed by
multiple technicians, in multiple assay plates, and during multiple
days. Therefore, speciﬁc attention to minimizing technically-induced
variability was vital. In addition to evaluation of several technical aspects,
reliability of single instead of multiple assessments per sample was
evaluated. A standard sample was repeatedly included in all assay
plates throughout the assessment period to quantify technically-induced
variability (3 levels: within plates, within all plates on a day, in all
plates throughout the assessment period) and evaluate adjustment for
between-plate variability.
Results: The additional variation that was introduced by single instead of
multiple sample assessments was limited and considered acceptable in the
context of logistics, scarcity of samples, and costs (triplicate assessment
in a subset of samples showed high correlation between biochemical
marker concentrations in the ﬁrst sample and the mean concentration
in triplets; rs 0.841–0.996, P 0.000). Of the 11,000 assessments that
were performed, 27 and 19 assessments showed concentrations that
were below or above the standard curve, respectively. Re-assessment in
adjusted dilutions induced (unpredictable) non-linear dilution effects
and was considered inappropriate. Instead, artiﬁcial concentrations
(0.8*minimum, 1.2*maximum concentration) were used. Technically-
induced variability increased stepwise between the 3 levels (intra-plate <
within day < total), but not statistically signiﬁcantly. Correction for
technically-induced between-plate variability on the basis of the standard
sample assessment that was performed in all plates decreased the CV% of
median biochemical marker concentrations between plates (mean ratio
after/before adjustment 0.96; SD 0.3). Three of the 11 biomarkers showed
unanticipated results. One could be re-assessed successfully, the other 2
remained unsolved, despite thorough analyses in consultancy with the
manufacturer.
Conclusions: Large-scale biochemical marker assessments pose speciﬁc
challenges. However, this study shows that large-scale assessment is
feasible for the vast majority of the studied biochemical markers.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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BIOMARKERS OF KNEE OSTEOARTHRITIS: CORRELATION WITH
OUTERBRIDGE CLASSIFICATION
J.M. Humphries1, C.J. Wilson2, D. Morgan3, G. Mercer2, J.S. Kuliwaba1,
N.L. Fazzalari1. 1SA Pathology, Adelaide, Australia; 2Repatriation Gen. Hosp.,
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Purpose: To determine if an association exists between circulating
concentrations of serum cartilage oligomeric matrix protein (COMP)
and fatty acids, and degree of osteoarthritic degradation of the medial
and lateral condyles of the tibial plateau graded according to the
Outerbridge Classiﬁcation, in patients undergoing total knee replacement
(TKR) surgery. Identiﬁcation of an easily accessible biomarker can aid in
determination of progressive osteoarthritis and in drug development.
Methods: Sera was collected from 113 individuals presenting for TKR,
representing both male (n =51) and female (n = 62) patients with an
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age range of 41–90 years. COMP levels were analysed by monoclonal
antibody enzyme linked immunosorbent assay in duplicate. The fatty
acid proﬁle of collected serum provided information on over 57
fatty acids determined by Gas Chromatography, though this report
focuses on the n-3, n-6 and n-9 types. The tibial plateau excised
during surgery was imaged and both medial and lateral condyles were
graded individually according to the Outerbridge Classiﬁcation by two
experienced orthopaedic surgeons.
Results: COMP values, serum fatty acid proﬁles and Outerbridge
Classiﬁcations were compared, and signiﬁcant positive correlations exist
between Outerbridge Classiﬁcation and total n-9 fatty acids (r = 0.235,
p < 0.05), and Outerbridge Classiﬁcation and 18:2(n-6) (linoleic-acid) (r
= 0.287, p < 0.05). There was a signiﬁcant negative correlation between
Outerbridge Classiﬁcation and 20:4(n-6) (arachidonic acid) (r = −0.336,
p < 0.01). Signiﬁcant correlations were also found to exist between the
various fatty acid groups and also within the n-6 and n-3 groups, as
would be expected.
Conclusion: Signiﬁcant correlations between the degree of tibial condyle
degradation and the level of overall n-9, linoleic-acid and arachidonic
acid show these to be of potential use as biomarkers of disease
progression. The ﬁnding of both positive and negative correlations
between the Outerbridge Classiﬁcation and n-6 fatty acids might
be explained by the ability of mammals to convert linoleic acid to
arachidonic acid. It is acknowledged that early-stage OA and controls
are lacking from this data-set, and that Outerbridge Classiﬁcations are
obtained at end-point OA.
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ANALYSIS OF CARTILAGE BIOMARKERS OF TURNOVER AND AGING
IN THE OSTEOARTHROPATHY OF ALKAPTONURIA
A.M. Taylor1,2, M-F. Hsueh2, L.R. Ranganath1, J.A. Gallagher1,
J.B. Catterall2, V.B. Kraus2. 1Univ. of Liverpool, Liverpool, United Kingdom;
2Duke Univ., Durham, NC, USA
Purpose: Alkaptonuria is a rare autosomal recessive condition resulting
from deﬁciency of homogentisate 1,2 dioxygenase (HGD) causing
inability to metabolise homogentisic acid (HGA). HGA levels in the
body become elevated and show high afﬁnity for collagenous tissues,
primarily articular cartilages of load bearing joints, where it polymerises
and deposits as a dark pigment; this process is ochronosis. Over time
ochronosis causes rapid and early onset joint arthropathy, mimicking
osteoarthritis (OA) in presentation. Little is known about how HGA and
pigment affect cartilage matrix. This study aims to examine the effects of
HGA and the pigment on matrix turnover of osteoarthritic AKU joints.
Methods: AKU (n=6), OA (n =12) and normal (NL from acute trauma,
n = 6) articular cartilages were obtained as surgical waste with IRB
approval. The soluble (GuHCl extracted) protein fractions were analysed
for glycosaminoglycan (GAG) content quantiﬁed by the dye-binding assay
with dimethylmethylene blue, total Cartilage Oligomeric Matrix Protein
(T-COMP) with monoclonal antibodies (mAbs) 16F12 and 17C10 (kindly
provided by Dr. V Vilim) and for the new deamidated-COMP (D-COMP)
with mAbs 61A12 and 17C10. GAG was normalized to total protein of
each sample and D-COMP was analyzed as a ratio to T-COMP. Statistical
analysis consisted of ANOVA with the Tukey-Kramer HSD post-hoc test
using JMP (SAS, Cary) software.
Results: Analysis of extractable GAG revealed a highly signiﬁcant
association with disease/cartilage type: AKU, OA, or NL (ANOVA
p < 0.0001). AKU cartilage shows a signiﬁcantly lower amount of
extractable GAG compared to both NL and OA (p < 0.0001). There was no
signiﬁcant difference between OA and NL although OA tended to be lower
than NL. GAG was also signiﬁcantly different by disease type for both
hips (p < 0.0001) and knees (p = 0.02). The ratio of D/T COMP was also
signiﬁcantly associated with disease/cartilage type (ANOVA p=0.017).
The ratio of D/T COMP in AKU vs NL and vs OA was signiﬁcantly
different (p = 0.028 and p=0.016 respectively), demonstrating that the
extractable COMP from AKU cartilages is quite aged. The D/T ratios were
not signiﬁcantly different between NL and OA. There were no associations
of GAG or D/T COMP with patient age.
Conclusions: These studies are the ﬁrst to analyze biomarkers of cartilage
matrix turnover in AKU tissues. Previous evidence shows cartilage matrix
in AKU does not turn over in a normal fashion, appearing impervious
to proteolytic enzymes. These results provide further insights into the
severely derangedmetabolism of AKU cartilages. Although AKUmanifests
as a rare OA phenotype, it is more extreme with much lower GAG
and much higher D/T COMP ratio indicative of severe degeneration and
absence of a repair response. Although we cannot be certain at this time
that GAG cannot be extracted due to being bound into the ochronotic
matrix, the signiﬁcantly higher D/T COMP ratio in the extractable protein
clearly indicates cartilage matrix in AKU is not turned over in a normal
manner, or even in a manner consistent with the pathological turnover
seen in OA. The clinical signiﬁcance of these results is important as
any potential therapeutic strategy would need to be given prior to
pigmentation occurring in the cartilage matrix of these individuals on
the basis of these results and would need to involve stimulation of a
cartilage reparative response.
160
THE DYNAMICS BETWEEN CYSTEINE PROTEASES AND
METALLOPROTEINASES IN HUMAN OA CARTILAGE
S.H. Madsen1, M. Andersen1, S.T. Christensen2, M.A. Karsdal1,
A-C. Bay-Jensen1. 1Nordic BioSci. A/S, Herlev, Denmark; 2Univ. of
Copenhagen, Copenhagen, Denmark
Purpose: Currently, treatment of osteoarthritis (OA) is either pain
relieving treatments or terminal surgery. Thus, the discovery and
development of new treatment strategies is needed. Proteases, such
as metalloproteinases and cathepsins, play a major role in the net
degradation of cartilage, and are therefore a natural target for drug
development. However, studies have suggested that inhibition of one
protease leads to a compensatory effects from another. We aim to
characterize the dynamics of the different proteases in normal and OA
cartilage. Furthermore, by testing the ability of a library of proteases to
degrade cartilage explants, and by inhibiting one type of proteases, we
aim to ﬁnd the proteases responsible for collagen type II and aggrecan
degradation and possible compensatory effects by other proteases.
Methods: We used an array of metallo- and cysteine-proteases (MMP-
1/3/7/9/13, ADAMTS-4/5, Cathepsin-K/B/D/L/S) to degrade the matrix
from human OA cartilage, independent of chondrocytes. Human OA
cartilage explants were metabolically inactivated by freeze-thaw cycles
and incubated individually for 9 h with the proteases ± MMP-inhibitor
(GM6001) or cysteine-inhibitor (E64), in an MMP- or cysteine-buffer
optimal for respective proteases.Furthermore, we cultured normal bovine
cartilage explants and murine femoral heads with the pro-inﬂammatory
cytokines, OSM + TNF-a ± inhibitors for 22 days. Biomarkers of cartilage-
degradation; AGNxII (aggrecan degradation), CTX-II (type II collagen
telopeptide fragment), CIIM (type II collagen C-terminal helical fragment)
and NBCII (type II collagen inter helical fragment) were used to evaluate
effects of the proteases and inhibitors on cartilage and femoral head
explants.
Results: MMP-3 and -7, and ADAMTS-4 and -5, all increased aggrecan
degradation (AGNxII), in human metabolic inactivated OA cartilage
incubated in buffer optimal for MMPs. GM6001 inhibited this release
of the aggrecan fragments. We did not see any release of AGNxII
fragments by MMP-1, -9 and -13. In addition, cathepsin-S increased
aggrecan degradation, whereas Cathepsin-K, -B, -D and -L decreased the
degradation of aggrecan. The cysteine inhibitor, E64, increased aggrecan
degradation in both MMP and cysteine buffer, and did not abrogate the
effects generated by the cathepsins on aggrecan. In the MMP buffer,
collagen type II degradation was only degraded with MMP-7 (CTX-II)
and MMP-9 (NBCII), which both could be inhibited by GM6001. In the
cysteine buffer, none of the cathepsins degraded collagen type II, whereas
GM6001 increased the degradation as assessed by all three markers (CTX-
II, CIIM and NBCII). Catabolic induced bovine cartilage increased aggrecan
(AGNxII) and collagen type II degradation (CIIM), which was inhibited by
GM6001 but increased in the presence of E64. Catabolic induced femoral
heads increased collagen type II degradation, which was inhibited by
GM6001, but we did not see any increase in presence of E64.
Conclusions: The presence and role of endogenous proteases probably
depend on the stage of OA, as we did not observe the same compensatory
effects in normal cytokine-stimulated cartilage as in OA cartilage when
incubated with E64. Thus more investigation on this topic may have
signiﬁcant value for development of new treatments for OA. Furthermore,
our data indicate that proteases are very dependent on extracellular
factors, as different buffers had signiﬁcant different inﬂuence on the
outcome.
